Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells.
OBJECTIVE
To compare the effect on corneal endothelial cells among intracameral moxifloxacin, levofloxacin and cefazoline in rabbits.


METHODS
Thirty-six eyes from eighteen rabbits were divided into four groups. The control solution (balanced salt solution), cefazolin 1000 microg/0.1 mL, levofloxain 500 microg/0.1 mL or moxifloxacin 500 microg/0.1 mL was injected into the anterior chamber of the rabbit eye. The central corneal thickness was assessed before the injection of intracameral antibiotics. Endothelial toxicity was evaluated according to the central corneal thickness, specular microscopy, scanning electron microscopy and transmission electron microscopy 1 day after injection.


RESULTS
Before the injection, the central corneal thickness was not different among four groups. After injection, there was no significant difference of the corneal thickness and endothelial cell count between the control and study groups. The central corneal thickness after injection of antibiotics did not significantly change when compared with control. Scanning electron microscopy showed normal hexagonality. Normal architecture of the endothelial cells was noted in transmission electron microscopy in all four groups.


CONCLUSIONS
Intracameral injection of antibiotics (cefazolin 1000 microg/0.1 mL, levofloxain 500 microg/0.1 mL, moxifloxacin 500 microg/0.1 mL) did not show significant toxicity on the endothelial cells compared with the control group. Intracameral injection of one of these antibiotics appears to be safe for surgical prophylaxis.
Kim
Su-Young
SY
Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea. cassiopeia@catholic.ac.kr
Park
Young-Hoon
YH
Lee
Young-Chun
YC
D000818:Animals; D000867:Anterior Chamber; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001372:Aza Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D002437:Cefazolin / Q000008:administration & dosage* / Q000494:pharmacology; D002452:Cell Count; D003315:Cornea / Q000033:anatomy & histology / Q000187:drug effects / Q000648:ultrastructure; D004728:Endothelium, Corneal / Q000166:cytology / Q000187:drug effects* / Q000648:ultrastructure; D024841:Fluoroquinolones; D007267:Injections; D064704:Levofloxacin; D008855:Microscopy, Electron, Scanning; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000008:administration & dosage* / Q000494:pharmacology; D011804:Quinolines / Q000008:administration & dosage* / Q000494:pharmacology; D011817:Rabbits
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D064704:Levofloxacin; D015242:Ofloxacin; D002437:Cefazolin; D000077266:Moxifloxacin